Understanding the Relationship Between Systemic and Hepatic Exposure of Obeticholic Acid for the Treatment of Liver Disease in Patients with Cirrhosis

Author(s): Jeffrey Edwards, Carl LaCerte, Thomas Peyret, Nathalie H. Gosselin, Jean-Francois Marier, Alan F. Hofmann, David Shapiro

Obeticholic acid (OCA) is a selective and potent farnesoid X receptor (FXR) agonist in development for several chronic liver diseases. OCA is a semi-synthetic analogue of chenodeoxycholic acid (CDCA) with similar pharmacokinetic (PK) properties. There was a significant increase in systemic exposure of OCA in patients with hepatic impairment. A proportionally similar increase in systemic exposure of endogenous bile acids was also observed in patients with hepatic impairment.

A physiologic PK model was developed based on a previously reported model for CDCA1 to define the relationship between systemic and hepatic exposure of OCA (and its pharmacologically active conjugates) in patients with and without hepatic impairment (cirrhosis).

Learn More LinkedIn Twitter Facebook Email